I agree and still believe that Lr-Et-EPA/MND-2119 is going to be in play at some point. Not sure if the idea is to wait and propose it to a BP to have them roll with it. But I would feel much more confident if a BP rolled it out, vs. Amarin doing it.
Just wish they could provide us with some indication of where they are going with it.
Zip, The number one mystery with Amarin for me is why no BP seems to be interested in Vascepa as an adjunct drug for any & all cancer drugs, treatments, & therapies. Surely Alex Denner has to be aware of the potential and I would think it would be a major selling point in attempting a BO. Imagine the potential benefit that Vascepa cold bring if a company such as Merck adopted Vascepa for use with Keytruda. My belief is that Vascepa use with any & all cancer therapies would result in better outcomes for the patients. Why is this something that is not more widely discussed? (Perhaps Alex Denner is doing this behind the scenes but does not want it disclosed for commercial reasons?)
News 
Market Data 
Discover 
